- Home
- GMAB vs WAFDP Comparison
GMAB vs WAFDP Comparison
Compare GMAB & WAFDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- WAFDP
- Stock Information
- Founded
- GMAB 1999
- WAFDP N/A
- Country
- GMAB Denmark
- WAFDP United States
- Employees
- GMAB N/A
- WAFDP 2208
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- WAFDP Major Banks
- Sector
- GMAB Health Care
- WAFDP Finance
- Exchange
- GMAB Nasdaq
- WAFDP Nasdaq
- Market Cap
- GMAB 12.8B
- WAFDP N/A
- IPO Year
- GMAB N/A
- WAFDP N/A
- Fundamental
- Price
- GMAB $20.95
- WAFDP $15.32
- Analyst Decision
- GMAB Buy
- WAFDP
- Analyst Count
- GMAB 9
- WAFDP 0
- Target Price
- GMAB $39.17
- WAFDP N/A
- AVG Volume (30 Days)
- GMAB 1.5M
- WAFDP N/A
- Earning Date
- GMAB 05-08-2025
- WAFDP N/A
- Dividend Yield
- GMAB N/A
- WAFDP N/A
- EPS Growth
- GMAB 276.13
- WAFDP N/A
- EPS
- GMAB 18.36
- WAFDP N/A
- Revenue
- GMAB $3,230,902,140.00
- WAFDP N/A
- Revenue This Year
- GMAB $17.69
- WAFDP N/A
- Revenue Next Year
- GMAB $14.81
- WAFDP N/A
- P/E Ratio
- GMAB $11.30
- WAFDP N/A
- Revenue Growth
- GMAB 25.21
- WAFDP N/A
- 52 Week Low
- GMAB $17.24
- WAFDP N/A
- 52 Week High
- GMAB $28.96
- WAFDP N/A
- Technical
- Relative Strength Index (RSI)
- GMAB 55.72
- WAFDP 28.96
- Support Level
- GMAB $20.73
- WAFDP $15.86
- Resistance Level
- GMAB $21.42
- WAFDP $16.47
- Average True Range (ATR)
- GMAB 0.45
- WAFDP 0.24
- MACD
- GMAB 0.11
- WAFDP -0.10
- Stochastic Oscillator
- GMAB 81.62
- WAFDP 0.00
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About WAFDP WaFd Inc. Depositary Shares
WaFd Inc is engaged in providing lending, depository, insurance, and other banking services to consumers, mid-sized to large businesses, and owners and developers of commercial real estate. Through the WaFd Bank, it is involved in accepting deposits from the general public and investing these funds in loans of various types, including first-lien mortgages on single-family dwellings, construction loans, land acquisition and development loans among others. The Bank also invests in certain United States government and agency obligations along with other investments and also performs insurance brokerage activities. Geographically, it operates in Washington, Oregon, Idaho, Arizona, Utah, Nevada, New Mexico, California and Texas.